Global Budesonide (BUD) Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Budesonide (BUD) Market Research Report 2024
Budesonide (BUD), sold under the brand name Pulmicort among others, is a steroid medication. It is available as an inhaler, pill, and Injectable Suspension. The inhaled form is used in the long term management of asthma and chronic obstructive pulmonary disease (COPD). The Injectable Suspension is used for allergic rhinitis and nasal polyps. The pills in a delayed release form may be used for inflammatory bowel disease including Crohn's disease, ulcerative colitis and microscopic colitis. Statistic for budesonide in this report includes three product typesInjectable Suspension, inhaler and Inhalation Powder.
According to Mr Accuracy reports’s new survey, global Budesonide (BUD) market is projected to reach US$ 12110 million in 2034, increasing from US$ 8203 million in 2024, with the CAGR of 5.6% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Budesonide (BUD) market research.
North America is the largest market with about 36% revenue market share. Followed by Asia-Pacific and Europe, accounting for about 60% revenue market share.
The key players are AstraZeneca, Teva, Mylan, Sandoz, Cosmo Pharmaceuticals, Salix, Chiesi Farmaceutici, Orion Corporation, Cipla, Synmosa Biopharma, Lunan Better Pharma, Shanghai Sine Promod etc. AstraZeneca is the largest manufacturer with about 56% revenue market share.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Budesonide (BUD) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
AstraZeneca
Cosmo Pharmaceuticals
Teva
Mylan
Sandoz
Dr. Falk Pharma
Chiesi Farmaceutici
Orion
Cipla
Synmosa Biopharma
Lunan Better Pharmaceutical
Shanghai Sine Promod Pharmaceutical
Segment by Type
Nasal Spray
Inhaler
Pill
Respiratory Disease Treatment
Nose Disease Treatment
Inflammatory Bowel Disease Treatment
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Budesonide (BUD) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Budesonide (BUD) market is projected to reach US$ 12110 million in 2034, increasing from US$ 8203 million in 2024, with the CAGR of 5.6% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Budesonide (BUD) market research.
North America is the largest market with about 36% revenue market share. Followed by Asia-Pacific and Europe, accounting for about 60% revenue market share.
The key players are AstraZeneca, Teva, Mylan, Sandoz, Cosmo Pharmaceuticals, Salix, Chiesi Farmaceutici, Orion Corporation, Cipla, Synmosa Biopharma, Lunan Better Pharma, Shanghai Sine Promod etc. AstraZeneca is the largest manufacturer with about 56% revenue market share.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Budesonide (BUD) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
AstraZeneca
Cosmo Pharmaceuticals
Teva
Mylan
Sandoz
Dr. Falk Pharma
Chiesi Farmaceutici
Orion
Cipla
Synmosa Biopharma
Lunan Better Pharmaceutical
Shanghai Sine Promod Pharmaceutical
Segment by Type
Nasal Spray
Inhaler
Pill
Segment by Application
Respiratory Disease Treatment
Nose Disease Treatment
Inflammatory Bowel Disease Treatment
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Budesonide (BUD) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices